论文部分内容阅读
美国西南肿瘤组既往用5天 OAP 方案,最佳的完全缓解率(CR)为43%,中数生存期为47周。为了探索延长阿糖胞甙(Ara-C)给药时间能否取得更高的 CR 率,作者将 Ara-C 给药时间延长至10天,其理论依据为:白血病原始细胞增殖周期平均为60小时,但可为48～240小时,延长 Ara-C 给药时间能作用于增殖周期长的白血病细胞而发挥更大的杀伤作用,从而获得更高的 CR 率和延长患者的生存时间。与此同时,作者还探索了免疫治疗的作用,观察了结核菌苗(BCG)接种对患者生存期的影响。
The Southwest Oncology Group had a 5-day OAP regimen with the best complete response rate (CR) of 43% and median survival of 47 weeks. In order to explore whether prolonged Ara-C administration can achieve a higher CR rate, the authors extend Ara-C administration to 10 days. The rationale is that the average proliferation cycle of leukemic blast cells is 60 Hour, but can be 48 ~ 240 hours, extend the Ara-C administration time can act on the proliferation of long-term leukemia cells and play a greater killing effect, resulting in higher CR rate and prolong survival time of patients. In the meantime, the authors also explored the role of immunotherapy in observing the impact of tuberculosis vaccine (BCG) vaccination on patient survival.